Estadístiques de Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
Visites totals
| views | |
|---|---|
| Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date | 201 |
Visites totals per mes
| views | |
|---|---|
| May 2025 | 3 |
| June 2025 | 0 |
| July 2025 | 0 |
| August 2025 | 0 |
| September 2025 | 0 |
| October 2025 | 0 |
| November 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| remon-cmr-nivo.pdf(legacy) | 201 |
| remon-cmr-nivo.pdf | 101 |
Vistes principals per país
| views | |
|---|---|
| United States | 134 |
| United Kingdom | 9 |
| Australia | 8 |
| Germany | 6 |
| Spain | 5 |
| Brazil | 4 |
| Japan | 4 |
| China | 3 |
| Egypt | 3 |
| Greece | 3 |
| South Korea | 3 |
| Sweden | 3 |
| Canada | 2 |
| Czechia | 2 |
| Hong Kong SAR China | 2 |
| France | 1 |
| India | 1 |
| Italy | 1 |
| Malaysia | 1 |
| Serbia | 1 |
| Slovakia | 1 |
Visites principals per ciutat
| views | |
|---|---|
| Ashburn | 18 |
| Fairfield | 17 |
| San Ramon | 14 |
| Redwood City | 12 |
| Mountain View | 6 |
| Menlo Park | 5 |
| Cambridge | 4 |
| Carapicuíba | 4 |
| Ridge | 4 |
| Tustin | 4 |
| Berkeley | 3 |
| Boardman | 3 |
| Leeds | 3 |
| Princeton | 3 |
| Seoul | 3 |
| Shenzhen | 3 |
| Tokyo | 3 |
| Bedworth | 2 |
| Cairo | 2 |
| Hong Kong | 2 |
| London | 2 |
| Los Angeles | 2 |
| Marblehead | 2 |
| Murcia | 2 |
| Sacramento | 2 |
| San Diego | 2 |
| Seattle | 2 |
| Sydney | 2 |
| Tallahassee | 2 |
| Thessaloníki | 2 |
| Albuquerque | 1 |
| Altamonte Springs | 1 |
| Ann Arbor | 1 |
| Arganda | 1 |
| Barcelona | 1 |
| Bethesda | 1 |
| Brisbane | 1 |
| Brooklyn | 1 |
| Charleston | 1 |
| Columbus | 1 |
| Kyoto | 1 |
| Maryborough | 1 |
| Middletown | 1 |
| Naples | 1 |
| Northolt | 1 |
| Patras | 1 |
| Petaling Jaya | 1 |
| Philadelphia | 1 |
| Pinjarra | 1 |
| Portland | 1 |
| Scarborough | 1 |
| Stockholm | 1 |
| Subotica | 1 |
| Tempe | 1 |
| Thane | 1 |
| Toronto | 1 |
| Valladolid | 1 |
| Wichita | 1 |
| Yellowknife | 1 |